Phase 2b Study of Zelicapavir in High-Risk Adults: RSVHR Topline Results September 29, 2025 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-loo ...